CING Stock Price Forecast & Analysis
According to the forecasts of 3 analysts, the average analyst target price for Cingulate Inc. is $4.25 over the next 12 months. Cingulate Inc’s average analyst rating is a “Strong Buy”, indicating a positive outlook for the stock. However, Stock Target Advisor’s own stock analysis of Cingulate Inc is Bearish, based on 1 positive signal and 4 negative signals.
At the last closing, Cingulate Inc’s stock price was $1.11. The stock price has increased by 4.72% over the past week and 11.00% over the past month, but has decreased by 14.62% over the last year. This suggests that the stock has experienced recent volatility but has been on a downward trend over the longer term.
Cingulate ADHD Trial Results
Cingulate (NASDAQ: CING) reported positive results from a study evaluating its tablet formulation of dexmethylphenidate, a compound approved by the US FDA for the treatment of attention deficit/hyperactivity disorder (ADHD). The biopharmaceutical company’s lead drug candidate, CTx-1301, is an investigational, extended-release tablet formulation of dexmethylphenidate. The trial demonstrated that CTx-1301 can be taken with or without food, and multiple pharmacokinetic measurements were taken, indicating a favorable tolerability profile. CING’s shares surged more 43 percent today in intraday trading as a catalysts of the positive news. Last month, the company had announced that it had started a late-stage trial for CTx-1301, with results expected in Q3 2023.
About Cingulate
Cingulate Inc is a clinical-stage biopharmaceutical company that is dedicated to developing novel product candidates for the treatment of attention-deficit/hyperactivity disorder (ADHD) and related disorders, such as anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
The company’s lead product candidates include CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of ADHD. These medications are both stimulants that work by increasing the levels of dopamine and norepinephrine in the brain, which can help to improve focus, attention, and impulse control. CTx-1301 is currently in phase 3 clinical trials, which are the final stages of testing before a drug can be approved for use by regulatory authorities.
In addition to its focus on ADHD, Cingulate Inc is also developing CTx-2103 for the treatment of anxiety disorders. CTx-2103 is a non-stimulant medication that is designed to reduce anxiety and improve mood by targeting specific receptors in the brain. This product candidate is still in the preclinical stage of development, which means that it has not yet been tested in humans.
Overall, Cingulate Inc is a company that is committed to developing innovative and effective treatments for ADHD and related disorders, with a focus on improving the quality of life for patients and their families.